Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-07-09

FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for JULUCA (dolutegravir and rilpivirine) submitted by ViiV Healthcare Company to update the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Juluca (dolutegravir + rilpivirine)

Snippet

SUPPL AP for JULUCA (DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE)